• 14 November 2025
    • journal article
    • review article
Abstract
Pulmonary arterial hypertension (PAH) creates a prothrombotic environment that may result in in situ pulmonary arterial thrombosis (PAT), a subtype that can resemble pulmonary embolism and chronic thromboembolic pulmonary hypertension (CTEPH) but requires different management. We conducted a narrative review of epidemiology, mechanisms, diagnostic differentiation, imaging (CT pulmonary angiography [CTPA], ventilation-perfusion [V/Q] scanning, echocardiography), and treatment of in situ PAT, and incorporated an institutional retrospective series (screened 2020-2025). In situ PAT typically appears on CTPA as central or wall-adherent thrombi within markedly dilated proximal pulmonary arteries, often without stenosis. Early V/Q scanning is useful to rule out CTEPH; non-segmental or mottled perfusion favors Group 1 PAH. Caliber metrics (PA diameter, PA/Ao) and RV strain indices (RV/LV, TAPSE) support but do not by themselves establish the diagnosis. Of 364 PAH patients screened, 7 (1.9%) met imaging criteria for in situ PAT; mean age 42 years, 71% female, 43% congenital heart disease. All had PA ≥30 mm and RV/LV ≥1; 71% had aneurysmal PA ≥40 mm; 71% had negative DVT Doppler. Functional and hemodynamic impairment was substantial. A stepwise workflow-DVT assessment, V/Q to exclude CTEPH, and targeted CTPA morphology interpreted with hemodynamics-facilitates accurate classification of in situ PAT and avoids misdirected CTEPH interventions. Therapy should begin with PAH-targeted treatment; anticoagulation should be individualized according to phenotype, bleeding risk, and clinical course.